Journal article

Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfa

Raphael Schiffmann, Markus Ries, Derek Blankenship, Kathy Nicholls, Atul Mehta, Joe TR Clarke, Robert D Steiner, Michael Beck, Bruce A Barshop, William Rhead, Michael West, Rick Martin, David Amato, Nitin Nair, Pedro Huertas

Genetics in Medicine | NATURE PUBLISHING GROUP | Published : 2013

Grants

Funding Acknowledgements

These studies and analyses were funded by Shire Human Genetic Therapies (HGT). Medical writing support for this article was provided by Ray Beck of UBC-Envision Group and was funded by Shire HGT.R.S. has received honoraria and research support from Shire Human Genetic Therapies (HGT), Amicus Therapeutics, and Genzyme. K.N. has served on the Fabry Outcomes Survey advisory board that is funded by Shire HGT and has received travel and research support from Shire HGT, Genzyme, and Amicus; her center participates in clinical trials funded by Shire HGT and Amicus. A. M. has received research support and speaking honoraria from Shire HGT, Genzyme, and Actelion. J.T.R.C. has received research funding, consultancy fees, and/or speaker fees from Shire HGT, Genzyme, and Actelion. R. D. S. has participated in clinical trials funded by TKT/Shire HGT, Actelion, Genzyme, Protalix/Pfizer, and BioMarin. He has had research support from TKT and has received speaking or consulting fees from TKT/Shire HGT, Amicus, Actelion, Genzyme, Zacharon, and BioMarin. M. B. has received unrestricted grants, honoraria, and travel support from Shire HGT, Genzyme, BioMarin, and Actelion. B. A. B. has received research support from Genzyme and has served on an advisory board for BioMarin. W. R. has received research funding, consultancy fees, and/or speaker fees from Shire HGT, Genzyme, Hyperion, Ucyclyd, and Actelion and has served on advisory boards for Shire HGT. M. W. has received research support from Shire HGT and Genzyme; has received speaking honoraria from Shire HGT, Genzyme, Amicus Therapeutics, and Sumitomo Pharma; and has participated in advisory boards for Shire HGT. M. R. was an employee of Shire HGT from 2006 to 2009; he has served on advisory boards for Alexion, GSK, and Amicus and has received consultancy honoraria from Alexion, Oxyrane, and Shire HGT. P. H. was an employee of Shire HGT from 2008 to 2011. R. M. and N. N are employees of Shire HGT. D. A. was an employee of Shire HGT from 2010 to 2012. D. B. declares no potential competing interests.